DelveInsight’s, “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2022,” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor: Overview
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is a serine protease involved in cholesterol homeostasis. After binding to the complex low-density lipoprotein (LDL)-receptor, PCSK9 induces its intracellular degradation, thus reducing serum LDL clearance. PCSK9 is mainly secreted by the liver, but it is also expressed to a lesser extent in other organs. Apart from the well-known activity concerning hepatic LDL receptor-mediated pathway, PCSK9 has been supposed to potentially interfere with vascular inflammation in atherogenesis. Vascular smooth muscle cells have been demonstrated to produce higher amounts of PCSK9 as compared to endothelial cells especially in an inflammatory microenvironment. Low shear stress regions increase PCSK9 expression within SMCs, while higher shear stress gradually reduced PCSK9 expression.
"Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor pipeline landscape is provided which includes the disease overview and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor treatment guidelines. The assessment part of the report embraces, in depth Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor.
This segment of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Emerging Drugs
Evolocumab: Amgen
Evolocumab (Repatha) is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated for the treatment of patients with high-risk cardiovascular disease without prior heart attack or stroke. It is being investigated for the treatment of familial hypercholesterolemia in pediatric patients.
ION449: Ionis Pharmaceuticals
ION449 (formerly IONIS-AZ4-2.5-LRx), also known as AZD8233, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is integrally involved in the regulation of LDL-cholesterol. Genetic studies have shown that individuals with life-long reduction of LDL-C due to reduced function of PCSK9 have substantially reduced risk of cardiovascular disease. Pharmacological inhibition of PCSK9 substantially lowers LDL-C. ION449 is designed to reduce the liver production of PCSK9 and lower the plasma level of LDL-C and thus reduce the risk of cardiovascular disease.
Further product details are provided in the report……..
This segment of the report provides insights about the different Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 14+ key companies which are developing the therapies for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor. The companies which have their Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Amgen.
DelveInsight’s report covers around 14+ products under different phases of clinical development like
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Evolocumab: Amgen
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ION449: Ionis Pharmaceuticals
Drug profiles in the detailed report…..
Early stage products (Phase I)
Drug Name: Company Name
Drug profiles in the detailed report…..
Preclinical stage products
Oral PCSK9 inhibitor: Esperion Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Key Companies
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Key Products
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor- Unmet Needs
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor- Market Drivers and Barriers
Appendix
List of Table
Table 1: Total Products for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Ionis Pharmaceuticals
• Akeso Biopharma
• Amgen
• Novo Nordisk
• Civi BioPharma
